Generation Bio Co Cash Flow Conversion Efficiency
Generation Bio Co cash flow conversion efficiency. Based on the latest financial reports, Generation Bio Co (GBIO) has a cash flow conversion efficiency ratio of -1.042x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-52.68 Million) by net assets ($50.56 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Generation Bio Co (2018–2024)
Cash flow conversion efficiency of Generation Bio Co from 2018 to 2024. This chart illustrates how Generation Bio Co's cash flow conversion efficiency has evolved over time, based on yearly financial data. View today's stock price for Generation Bio Co for real-time trading data and today's change.
Generation Bio Co Cash Flow Conversion Ratio Explained
Generation Bio Co cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Generation Bio Co Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Generation Bio Co ranked by their cash flow conversion efficiency. Also see GBIO market cap for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
TAEYANG Corporation
KQ:053620
|
-0.010x |
|
Beaconsmind AG
PA:MLBMD
|
-1.608x |
|
Cranswick PLC
LSE:CWK
|
0.157x |
|
VerticalScope Holdings Inc
TO:FORA
|
0.048x |
|
Vintcom Technology PCL
BK:VCOM
|
0.083x |
|
Atakule Gayrimenkul Yatirim Ortakligi AS
IS:AGYO
|
0.006x |
|
Burcelik Bursa Celik Dokum Sanayi AS
IS:BURCE
|
-0.387x |
|
Lesico Ltd
TA:LSCO
|
0.226x |
Annual Cash Flow Conversion Efficiency for Generation Bio Co (2018–2024)
The table below shows the annual cash flow conversion efficiency of Generation Bio Co from 2018 to 2024. Review GBIO cash flow after capex ratio to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $86.20 Million | $-88.56 Million | -1.027x | -295.65% |
| 2023-12-31 | $203.13 Million | $-52.74 Million | -0.260x | +28.40% |
| 2022-12-31 | $282.49 Million | $-102.45 Million | -0.363x | -50.77% |
| 2021-12-31 | $381.75 Million | $-91.82 Million | -0.241x | +8.09% |
| 2020-12-31 | $268.01 Million | $-70.14 Million | -0.262x | -163.95% |
| 2019-12-31 | $-98.59 Million | $-40.35 Million | 0.409x | -39.47% |
| 2018-12-31 | $-41.59 Million | $-28.12 Million | 0.676x | -- |
About Generation Bio Co
Generation Bio Co., a biotechnology company, discovers, develops, and commercializes redosable therapeutics that reprogram T cells in vivo to reduce or eliminate the production and persistence of autoreactive T cells. It develops cell-targeted lipid nanoparticles (ctLNP) to selectively deliver small interfering RNA (siRNA) T cells to selectively delivery, intracellular, and genetically precise me… Read more